Literature DB >> 17662901

New and experimental treatments of cloasma and other hypermelanoses.

Mauro Picardo1, Manuela Carrera.   

Abstract

In clinical practice, acquired hyperpigmentations represent the most common disorders of pigmentation the dermatologist has to treat. Despite the large number of depigmenting agents available, the treatment of hyperpigmentations is often unsuccessful and disappointing and is still a challenge for dermatologists. This article focuses on the chemical compounds reported to be in depigmenting or skin lightening agents, their proposed mechanism of action, and their clinical efficacy in the treatment of melasma and hypermelanoses, mainly based on randomized clinical trials. It also reviews chemical peels and their indications, together with the possible uses of laser and intense pulsed light.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662901     DOI: 10.1016/j.det.2007.04.012

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  10 in total

Review 1.  [Fractional photothermolysis: a new option for treating melasma?].

Authors:  S Karsai; C Raulin
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

2.  Solamargine Alleviated UVB-Induced Inflammation and Melanogenesis in Human Keratinocytes and Melanocytes via the p38 MAPK Signaling Pathway, a Promising Agent for Post-inflammatory Hyperpigmentation.

Authors:  Juemin Zhao; Yanjun Dan; Ziqi Liu; Qianqian Wang; Min Jiang; Chengfeng Zhang; Hamm-Ming Sheu; Chrang-Shi Lin; Leihong Xiang
Journal:  Front Med (Lausanne)       Date:  2022-06-13

3.  Acquired brachial cutaneous dyschromatosis in a 60-year-old male: a case report and review of the literature.

Authors:  Nadia Abidi; Kristen Foering; Joya Sahu
Journal:  Case Rep Dermatol Med       Date:  2014-12-31

Review 4.  Antioxidants in dermatology.

Authors:  Flavia Alvim Sant'anna Addor
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

Review 5.  Fermented broth in tyrosinase- and melanogenesis inhibition.

Authors:  Chin-Feng Chan; Ching-Cheng Huang; Ming-Yuan Lee; Yung-Sheng Lin
Journal:  Molecules       Date:  2014-08-26       Impact factor: 4.411

6.  Topical treatment of melasma.

Authors:  Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

Review 7.  Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration.

Authors:  Jody P Ebanks; R Randall Wickett; Raymond E Boissy
Journal:  Int J Mol Sci       Date:  2009-09-15       Impact factor: 6.208

8.  Lasers for treatment of melasma and post-inflammatory hyperpigmentation.

Authors:  Pooja Arora; Rashmi Sarkar; Vijay K Garg; Latika Arya
Journal:  J Cutan Aesthet Surg       Date:  2012-04

9.  Azastilbene analogs as tyrosinase inhibitors: new molecules with depigmenting potential.

Authors:  Larissa Lavorato Lima; Rebeca Mól Lima; Annelisa Farah da Silva; Antônio Márcio Resende do Carmo; Adilson David da Silva; Nádia Rezende Barbosa Raposo
Journal:  ScientificWorldJournal       Date:  2013-02-12

10.  Inhibitory effects of resveratrol analogs on mushroom tyrosinase activity.

Authors:  Danielle Cristina Zimmermann Franco; Gustavo Senra Gonçalves de Carvalho; Paula Rafaela Rocha; Raquel da Silva Teixeira; Adilson David da Silva; Nádia Rezende Barbosa Raposo
Journal:  Molecules       Date:  2012-10-09       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.